Sulfamoxole API is a synthetic sulfonamide antibacterial active pharmaceutical ingredient belonging to the sulfonamide class of antimicrobial compounds. It is chemically identified as 4-amino-N-(4,5-dimethyl-1,3-oxazol-2-yl)benzenesulfonamide and is also known by names including Sulfamoxol, Sulphamoxole, Sulfadimethyloxazole and N¹-(4,5-Dimethyloxazol-2-yl)sulfanilamide. Sulfamoxole has the molecular formula C₁₁H₁₃N₃O₃S, molecular weight 267.31 g/mol, and CAS Number 729-99-7.
Sulfamoxole is a member of the sulfonamide antibacterial class and acts by interfering with bacterial folate metabolism. It is recognized as an antibacterial compound and has historically been used as a sulfonamide antimicrobial, including in combination with trimethoprim in certain pharmaceutical applications.
Sulfamoxole contains a p-aminobenzenesulfonamide structure linked to a 4,5-dimethyl-1,3-oxazole ring. Its IUPAC name is 4-amino-N-(4,5-dimethyl-1,3-oxazol-2-yl)benzenesulfonamide.
The API has the molecular formula C₁₁H₁₃N₃O₃S and molecular weight 267.31 g/mol. NIST independently reports a molecular weight of 267.304 g/mol and CAS Registry Number 729-99-7.
Sulfamoxole is generally described as an off-white to pale-yellow solid. Published chemical-reference data report a melting range around 197–199°C, although reference-standard suppliers can report somewhat different ranges depending on the material and analytical method.
Sulfamoxole is a sulfonamide antibacterial API. It has historically been used for the treatment of susceptible bacterial infections and is associated with the sulfonamide antimicrobial class.
Historical pharmaceutical use includes Sulfamoxole-containing antibacterial preparations, including combinations with trimethoprim. Sulfamoxole + trimethoprim combinations have been investigated and used under the name co-trimoxole/co-trifamole in some pharmaceutical contexts.
The actual indication, formulation, dosage, target population and regulatory status depend on the finished medicinal product and applicable market authorization.
Sulfamoxole belongs to the sulfonamide antibacterial class. Sulfonamides act as structural analogues of para-aminobenzoic acid (PABA) and interfere with bacterial folate biosynthesis.
Sulfamoxole inhibits the bacterial folate pathway, particularly the enzyme dihydropteroate synthase, reducing the formation of folate intermediates required for bacterial nucleic-acid synthesis.
This interference with folate metabolism inhibits the growth and multiplication of susceptible bacteria.
Sulfamoxole is chemically well characterized, but unlike products such as Sulfamethoxazole, Sulfamethizole and several other commonly marketed sulfonamides, I could not verify a current USP, BP or Ph. Eur. monograph with authoritative numerical release specifications for Sulfamoxole from the sources reviewed.
Therefore, numerical assay, impurity, loss-on-drying and residue-on-ignition limits should not be invented or presented as universal pharmacopoeial requirements.
Analytical evaluation of Sulfamoxole API may include:
Commercial analytical standards demonstrate that Sulfamoxole can be characterized by HPLC; however, an analytical-standard purity such as ≥95% should not be represented as a pharmaceutical API release specification.
Swapnroop Drugs and Pharmaceuticals provides pharmaceutical API manufacturing and quality-support capabilities for Sulfamoxole, with analytical evaluation based on applicable customer specifications and pharmaceutical quality requirements.
Sulfamoxole API can be evaluated for identity, assay, related substances, loss on drying, residue on ignition, residual solvents and other applicable quality parameters according to the agreed specification.
For pharmaceutical manufacturers seeking Sulfamoxole API from India, product specifications, analytical documentation and commercial requirements can be evaluated according to the intended application and applicable regulatory market.
Sulfamoxole should be maintained in suitable well-closed pharmaceutical-grade packaging that protects the material from moisture, contamination and excessive environmental exposure.
Storage conditions should be established according to the approved product specification and stability data. Reference-standard suppliers may specify refrigerated storage, but such conditions should not automatically be presented as the commercial API storage requirement without supporting stability data.
Depending on customer and regulatory requirements, documentation may include:
Sulfamoxole is an established sulfonamide antibacterial compound with well-defined chemical identity and physicochemical characteristics. PubChem and NIST confirm its CAS 729-99-7, molecular formula C₁₁H₁₃N₃O₃S and molecular weight of approximately 267.31 g/mol.
Swapnroop Drugs and Pharmaceuticals focuses on controlled pharmaceutical API manufacturing, analytical quality evaluation and documentation support for customers requiring Sulfamoxole API.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Melting Point | Approximately 197–199°C |